Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menveo 1 vs 2 Doses in Children 2-10 Years
NCT01682876Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Primary completion
- Jul 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine in meningococcal disease, sponsored by GSK. Started Oct 2012; status: completed.
02
Drugs
Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01682876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682876.